Clear Harbor Asset Management LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Clear Harbor Asset Management LLC lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 10,816 shares of the medical research company’s stock after buying an additional 850 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $5,741,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TMO. Phoenix Holdings Ltd. raised its position in shares of Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after buying an additional 1,654 shares during the last quarter. DMC Group LLC increased its holdings in Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares during the last quarter. Montchanin Asset Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.1% during the 2nd quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company’s stock valued at $2,374,000 after purchasing an additional 50 shares during the last quarter. Check Capital Management Inc. CA purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $219,000. Finally, Tower Bridge Advisors lifted its position in shares of Thermo Fisher Scientific by 0.5% in the third quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company’s stock worth $16,727,000 after buying an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded up $1.84 during mid-day trading on Thursday, reaching $581.21. 1,034,640 shares of the company’s stock were exchanged, compared to its average volume of 1,617,943. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company has a market cap of $221.62 billion, a price-to-earnings ratio of 37.62, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. The stock’s 50 day moving average is $565.13 and its 200 day moving average is $520.22. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.40 earnings per share. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 over the last ninety days. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on TMO. HSBC started coverage on Thermo Fisher Scientific in a research note on Monday, December 18th. They issued a “buy” rating and a $610.00 price objective on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.